{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:00:59Z","timestamp":1770814859239,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiochemotherapy with the apoptosis stimulator xevinapant demonstrated superiority over radiochemotherapy in a randomized phase 2 trial in head and neck squamous cell carcinoma (HNSCC) but the subsequent phase 3 trial failed. Here, we compared the radiosensitization through xevinapant with two other emerging approaches, the inhibition of ATR and PARP through tuvusertib and olaparib, in a panel of four radioresistant HPV-negative HNSCC cell lines (HSC4, UT-SCC-60A, SAS, SAT). Without irradiation the analyses of proliferation and colony formation showed varying sensitivities of the cell lines towards the different agents and their combinations. When combined with radiation in colony formation assays, we observed moderate radiosensitization through xevinapant in individual cell lines but not in general. Both tuvusertib and olaparib induced stronger radiosensitization than xevinapant and combining both agents resulted in especially profound radiosensitization in three out of the four cell lines tested, whereas their combination with xevinapant or the combination of xevinapant with cisplatin was less effective. Assessment of cell death induction via annexin V\/DAPI staining failed to generally predict cytotoxicity or radiosensitization of these approaches. Overall, our data are in line with the recent failure of the phase 3 TrilynX trial and suggest further investigation of ATR and PARP inhibition for the curative treatment of HPV-negative HNSCC.<\/jats:p>","DOI":"10.1038\/s41598-026-38550-3","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:25:31Z","timestamp":1770787531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Julius","family":"Roehrle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Perugachi-Heinsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fruzsina","family":"Gatzemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordula","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Rothkamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Betz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kriegs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrike Barbara","family":"Zech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"38550_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.surge.2018.04.009","volume":"17","author":"N Ahmadi","year":"2019","unstructured":"Ahmadi, N., Chan, M., Huo, Y. R., Sritharan, N. & Chin, R. Y. Survival outcome of tonsillar squamous cell carcinoma (TSCC) in the context of human papillomavirus (HPV): A systematic review and meta-analysis. Surgeon 17, 6\u201314. https:\/\/doi.org\/10.1016\/j.surge.2018.04.009 (2019).","journal-title":"Surgeon"},{"key":"38550_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/09553002.2022.2110301","volume":"99","author":"D Avril","year":"2023","unstructured":"Avril, D., Foy, J. P., Bouaoud, J., Gregoire, V. & Saintigny, P. Biomarkers of radioresistance in head and neck squamous cell carcinomas. Int. J. Radiat. Biol. 99, 583\u2013593. https:\/\/doi.org\/10.1080\/09553002.2022.2110301 (2023).","journal-title":"Int. J. Radiat. Biol."},{"key":"38550_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers 6, 92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"38550_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctro.2022.03.009","volume":"34","author":"S Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, S. et al. The dogma of Cetuximab and Radiotherapy in head and neck cancer\u2014A dawn to dusk journey. Clin. Transl. Radiat. Oncol. 34, 75\u201381. https:\/\/doi.org\/10.1016\/j.ctro.2022.03.009 (2022).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"38550_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.radonc.2015.05.017","volume":"116","author":"O Matzinger","year":"2015","unstructured":"Matzinger, O. et al. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFalpha-mediated in head and neck squamous cell carcinoma. Radiother. Oncol. 116, 495\u2013503. https:\/\/doi.org\/10.1016\/j.radonc.2015.05.017 (2015).","journal-title":"Radiother. Oncol."},{"key":"38550_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2022.12.015","volume":"183","author":"Y Tao","year":"2023","unstructured":"Tao, Y. et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Eur. J. Cancer 183, 24\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.015 (2023).","journal-title":"Eur. J. Cancer"},{"key":"38550_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00272","author":"J Bourhis","year":"2025","unstructured":"Bourhis, J. et al. Xevinapant or placebo plus platinum-based chemoradiotherapy in unresected locally advanced squamous cell carcinoma of the head and neck (TrilynX): A randomized phase III study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-00272 (2025).","journal-title":"J. Clin. Oncol."},{"key":"38550_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.semradonc.2025.02.008","volume":"35","author":"A Sobti","year":"2025","unstructured":"Sobti, A., Skinner, H. & Wilke, C. T. Predictors of radiation resistance and novel radiation sensitizers in head and neck cancers: Advancing radiotherapy efficacy. Semin. Radiat. Oncol. 35, 224\u2013242. https:\/\/doi.org\/10.1016\/j.semradonc.2025.02.008 (2025).","journal-title":"Semin. Radiat. Oncol."},{"key":"38550_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00066-023-02064-y","volume":"199","author":"K Viktorsson","year":"2023","unstructured":"Viktorsson, K. et al. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy. Strahlenther. Onkol. 199, 1091\u20131109. https:\/\/doi.org\/10.1007\/s00066-023-02064-y (2023).","journal-title":"Strahlenther. Onkol."},{"key":"38550_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117804","volume":"296","author":"S Guo","year":"2025","unstructured":"Guo, S. et al. Research progress of ATR small molecule inhibitors in cancer therapy. Eur. J. Med. Chem. 296, 117804. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117804 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"38550_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Targeting ATR in patients with cancer. Nat. Rev. Clin. Oncol. 21, 278\u2013293. https:\/\/doi.org\/10.1038\/s41571-024-00863-5 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"38550_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","volume":"23","author":"U Jo","year":"2024","unstructured":"Jo, U. et al. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Mol. Cancer Ther. 23, 911\u2013923. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0402 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"38550_CR13","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna, C. et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: Results of the phase I OPARATIC trial. Neuro Oncol. 22, 1840\u20131850. https:\/\/doi.org\/10.1093\/neuonc\/noaa104 (2020).","journal-title":"Neuro Oncol."},{"key":"38550_CR14","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/1078-0432.CCR-20-0425","volume":"26","author":"C Le Tourneau","year":"2020","unstructured":"Le Tourneau, C. et al. Phase I trial of Debio 1143, an antagonist of inhibitor of apoptosis proteins, combined with cisplatin chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Clin. Cancer Res. 26, 6429\u20136436. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0425 (2020).","journal-title":"Clin. Cancer Res."},{"key":"38550_CR15","doi-asserted-by":"publisher","first-page":"9426","DOI":"10.26355\/eurrev_202212_30694","volume":"26","author":"J Stanislawiak-Rudowicz","year":"2022","unstructured":"Stanislawiak-Rudowicz, J. et al. The use of Ctrough for the therapeutic drug monitoring of olaparib in patients with ovarian cancer. Eur. Rev. Med. Pharmacol. Sci. 26, 9426\u20139436. https:\/\/doi.org\/10.26355\/eurrev_202212_30694 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"38550_CR16","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1158\/1078-0432.CCR-18-3802","volume":"25","author":"R Xiao","year":"2019","unstructured":"Xiao, R. et al. Dual antagonist of cIAP\/XIAP ASTX660 sensitizes HPV(-) and HPV(+) head and neck cancers to TNFalpha, TRAIL, and radiation therapy. Clin. Cancer Res. 25, 6463\u20136474. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3802 (2019).","journal-title":"Clin. Cancer Res."},{"key":"38550_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139837","author":"B Uzunparmak","year":"2020","unstructured":"Uzunparmak, B. et al. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.139837 (2020).","journal-title":"JCI Insight"},{"key":"38550_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.ijrobp.2011.02.043","volume":"80","author":"U Kasten-Pisula","year":"2011","unstructured":"Kasten-Pisula, U. et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification. Int. J. Radiat. Oncol. Biol. Phys. 80, 1181\u20131188. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.043 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"38550_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100630","volume":"41","author":"A Oetting","year":"2023","unstructured":"Oetting, A. et al. Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1. Clin. Transl. Radiat. Oncol. 41, 100630. https:\/\/doi.org\/10.1016\/j.ctro.2023.100630 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"38550_CR20","doi-asserted-by":"publisher","first-page":"35832","DOI":"10.18632\/oncotarget.9028","volume":"7","author":"CJ Busch","year":"2016","unstructured":"Busch, C. J. et al. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines. Oncotarget 7, 35832\u201335842. https:\/\/doi.org\/10.18632\/oncotarget.9028 (2016).","journal-title":"Oncotarget"},{"key":"38550_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas, B. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group. Radiother. Oncol. 156, 281\u2013293. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.013 (2021).","journal-title":"Radiother. Oncol."},{"key":"38550_CR22","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","volume":"75","author":"SU Ahmed","year":"2015","unstructured":"Ahmed, S. U. et al. Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res. 75, 4416\u20134428. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3790 (2015).","journal-title":"Cancer Res."},{"key":"38550_CR23","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","volume":"20","author":"D Karnak","year":"2014","unstructured":"Karnak, D. et al. Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer. Clin. Cancer Res. 20, 5085\u20135096. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1038 (2014).","journal-title":"Clin. Cancer Res."},{"key":"38550_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1541-7786.MCR-17-0455","volume":"16","author":"LA Parsels","year":"2018","unstructured":"Parsels, L. A. et al. PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors. Mol. Cancer Res. 16, 222\u2013232. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0455 (2018).","journal-title":"Mol. Cancer Res."},{"key":"38550_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.radonc.2014.10.011","volume":"113","author":"JD Guster","year":"2014","unstructured":"Guster, J. D. et al. The inhibition of PARP but not EGFR results in the radiosensitization of HPV\/p16-positive HNSCC cell lines. Radiother. Oncol. 113, 345\u2013351. https:\/\/doi.org\/10.1016\/j.radonc.2014.10.011 (2014).","journal-title":"Radiother. Oncol."},{"key":"38550_CR26","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.4161\/cc.10.24.18661","volume":"10","author":"S Vance","year":"2011","unstructured":"Vance, S. et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 10, 4321\u20134329. https:\/\/doi.org\/10.4161\/cc.10.24.18661 (2011).","journal-title":"Cell Cycle"},{"key":"38550_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683688","volume":"11","author":"K Hintelmann","year":"2021","unstructured":"Hintelmann, K. et al. Dual inhibition of PARP and the intra-S\/G2 cell cycle checkpoints results in highly effective radiosensitization of HPV-positive hnscc cells. Front Oncol 11, 683688. https:\/\/doi.org\/10.3389\/fonc.2021.683688 (2021).","journal-title":"Front Oncol"},{"key":"38550_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","volume":"20","author":"LA Parsels","year":"2021","unstructured":"Parsels, L. A. et al. Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer. Mol. Cancer Ther. 20, 263\u2013273. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0365 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"38550_CR29","doi-asserted-by":"publisher","unstructured":"Kristeleit, R. et al. DDRiver EOC 302: A Randomised Phase 2 Study Of Tuvusertib With Niraparib Or Lartesertib In Patients With Epithelial OvarianCancer That Has Progressed On Prior PARP Inhibitor Therapy. International Journal of Gynecological Cancer,  35 (2), 101597.https:\/\/doi.org\/10.1016\/j.ijgc.2024.101597","DOI":"10.1016\/j.ijgc.2024.101597"},{"key":"38550_CR30","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1200\/JCO.2024.42.16_suppl.3018","volume":"42","author":"TA Y","year":"2024","unstructured":"Yap, T.A. et al. A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solidtumors. J Clin Oncol 42, 3018 (2024). https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3018.","journal-title":"JCO"},{"key":"38550_CR31","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","volume":"24","author":"SD Karam","year":"2018","unstructured":"Karam, S. D. et al. Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer. Clin. Cancer Res. 24, 4949\u20134959. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0467 (2018).","journal-title":"Clin. Cancer Res."},{"key":"38550_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100698","volume":"44","author":"A Navran","year":"2024","unstructured":"Navran, A. et al. Phase I feasibility study of olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma. Clin. Transl. Radiat. Oncol. 44, 100698. https:\/\/doi.org\/10.1016\/j.ctro.2023.100698 (2024).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"38550_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100614","volume":"40","author":"H Sheikh","year":"2023","unstructured":"Sheikh, H., Ryder, D., Bateman, A., Chalmers, A. & Jackson, A. Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study. Clin. Transl. Radiat. Oncol. 40, 100614. https:\/\/doi.org\/10.1016\/j.ctro.2023.100614 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"38550_CR34","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","volume":"27","author":"R de Haan","year":"2021","unstructured":"de Haan, R. et al. Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer. Clin. Cancer Res. 27, 1256\u20131266. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2551 (2021).","journal-title":"Clin. Cancer Res."},{"key":"38550_CR35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ijrobp.2024.01.011","volume":"118","author":"S Derby","year":"2024","unstructured":"Derby, S. et al. Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: The phase 1 dose-escalation PARADIGM trial. Int. J. Radiat. Oncol. Biol. Phys. 118, 1371\u20131378. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.011 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"38550_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A. & Ngoi, N. PARP inhibitors: Enhancing efficacy through rational combinations. Br J Cancer 129, 904\u2013916. https:\/\/doi.org\/10.1038\/s41416-023-02326-7 (2023).","journal-title":"Br J Cancer"},{"key":"38550_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N. Engl. J. Med. 393, 37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434 (2025).","journal-title":"N. Engl. J. Med."},{"key":"38550_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels, J. P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): A randomised, double-blind, phase 3 trial. Lancet Oncol. 25, 572\u2013587. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1 (2024).","journal-title":"Lancet Oncol."},{"key":"38550_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","volume":"34","author":"Y Tao","year":"2023","unstructured":"Tao, Y. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015\u201301 PembroRad): A multicenter, randomized, phase II trial. Ann. Oncol. 34, 101\u2013110. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.006 (2023).","journal-title":"Ann. Oncol."},{"key":"38550_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450\u2013462. https:\/\/doi.org\/10.1016\/S1470-2045(20)30737-3 (2021).","journal-title":"Lancet Oncol."},{"issue":"Supplement 5","key":"38550_CR41","doi-asserted-by":"publisher","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","volume":"32","author":"J B","year":"2021","unstructured":"Bourhis, J. et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head andneck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Annals of oncology, 2021, 32(Suppl 5), S1310 (2021).https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2112","journal-title":"Ann. Oncol."},{"key":"38550_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison, M. L. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 393, 40\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(18)32779-X (2019).","journal-title":"Lancet"},{"key":"38550_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna, H. et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet 393, 51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(18)32752-1 (2019).","journal-title":"Lancet"},{"key":"38550_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","volume":"111","author":"D Rischin","year":"2021","unstructured":"Rischin, D. et al. Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk hpv-associated oropharyngeal cancer (TROG 12.01)\u2014A trans-tasman radiation oncology group study. Int. J. Radiat. Oncol. Biol. Phys. 111, 876\u2013886. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.015 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"38550_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2020.10.035","volume":"498","author":"EN Alsahafi","year":"2021","unstructured":"Alsahafi, E. N. et al. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation. Cancer Lett. 498, 80\u201397. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.035 (2021).","journal-title":"Cancer Lett."},{"key":"38550_CR46","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/ijc.33606","volume":"149","author":"L Bussmann","year":"2021","unstructured":"Bussmann, L. et al. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. Int. J. Cancer 149, 1166\u20131180. https:\/\/doi.org\/10.1002\/ijc.33606 (2021).","journal-title":"Int. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38550-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:51:47Z","timestamp":1770803507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38550-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38550"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38550-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5882"}}